

Creating Diverse Target-Binding Surfaces on FKBP12: Synthesis and Evaluation of a Rapamycin Analogue Library

Xianghong Wu,[†]Lisheng Wang,[‡] Yaohua Han,[§] Nicholas Regan,[‡] Pui-Kai Li,[‡] Miguel A. Villalona,^{&,[^]} Xiche Hu,[§] Roger Briesewitz,^{*,‡,[^]} Dehua Pei^{*,[†],[^]}


Supporting Information

Table of Contents

Figure S1. ^1H NMR, ^{13}C NMR, and HR MS of Compounds 4 , 5 , and 3a-c	2
Figure S2. ESI MS of Rapalogs 2a-y in Table 1	12
Figure S3. MALDI-TOF MS of Rapalogs 11 in Table 2	21
Figure S4. MALDI-TOF MS of Rapalogs 12 in Table 2	54
Figure S5. Representative titration curves of FA competition assay of rapalogs	86

Figure S1. ^1H NMR, ^{13}C NMR, and High-Resolution MS of Compounds **4**, **5**, and **3a-c**

Compound **4**



Display Report




Analysis Info

Analysis Name D:\Data\pe\xwu\6 901029.d
Method 75 to 200.m
Sample Name
Comment


Acquisition Date 10/29/2009 2:45:48 PM
Operator xwu
Instrument / Ser# micrOTOF 194

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Active			Set Dry Heater	200 °C
Scan Begin	50 m/z	Set Capillary	4500 V	Set Dry Gas	4.0 l/min
Scan End	300 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Waste



Compound 5



Display Report




Analysis Info

Analysis Name D:\Data\pe\xwu\7 901029.d
Method 100 to 500.m
Sample Name
Comment


Acquisition Date 10/29/2009 2:53:05 PM
Operator xwu
Instrument / Ser# micrOTOF 194

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Active			Set Dry Heater	200 °C
Scan Begin	50 m/z	Set Capillary	4500 V	Set Dry Gas	4.0 l/min
Scan End	600 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Waste



Compound 3a



Display Report



Analysis Info

Analysis Name D:\Data\pe\xwu\21-4 901029.d
Method 300 to 900.m
Sample Name
Comment


Acquisition Date 10/29/2009 3:50:19 PM
Operator xwu
Instrument / Ser# micrOTOF 194

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Active			Set Dry Heater	200 °C
Scan Begin	200 m/z	Set Capillary	4500 V	Set Dry Gas	4.0 l/min
Scan End	1000 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Waste



Compound 3b



Display Report




Analysis Info

Analysis Name D:\Data\peixwu\21-3 901029.d
Method 300 to 900.m
Sample Name
Comment


Acquisition Date 10/29/2009 3:42:03 PM
Operator xwu
Instrument / Ser# micrOTOF 194

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Active			Set Dry Heater	200 °C
Scan Begin	200 m/z	Set Capillary	4500 V	Set Dry Gas	4.0 l/min
Scan End	1000 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Waste



Compound 3c



Display Report

Analysis Info

Analysis Name D:\Data\pei\xwu\Thr deallyl final buildblock 100714.d
Method 300 to 900.m
Sample Name
Comment

Acquisition Date 7/14/2010 5:04:56 PM
Operator xwu
Instrument / Ser# micrOTOF 194

Acquisition Parameter

Source Type ESI
Focus Active
Scan Begin 200 m/z
Scan End 1000 m/z
Ion Polarity Set Capillary
Set End Plate Offset Positive
Set Nebulizer 4500 V
Set Dry Heater -500 V
Set Dry Gas 0.4 Bar
Set Divert Valve 200 °C
Waste 4.0 l/min






Figure S2. ESI MS of Rapalogs **2a-y** in Table 1


2a




2b




2c




2d




2e




2f




2g




2h




2i




2j




2k




2l




2m




2n




2o




2p




2q




2r




2s



2t




2u




2v


+MS, 0.2min #(9)



2w



2x








Figure S3. MALDI-TOF MS of Rapalog **11** in Table 2


11 D-Thr-D-Thr




11 D-Thr-Gly




11 D-Thr-Ala




11 D-Thr-D-Val




11 D-Thr-Pro




11 D-Thr-Lys




11 D-Thr-Asp




11 D-Thr-D-Phe




11 D-Thr-Nle




11 Gly-D-Thr




11 Gly-Gly




11 Gly-Ala




11 Gly-D-Val




11 Gly-Pro




11 Gly-Lys



11 Gly-Trp




11 Gly-Asp




11 Gly-D-Phe




11 Gly-Nle






11 Ala-D-Thr




11 Ala-Gly




11 Ala-Ala**11 Ala-D-Val****11 Ala-Pro**


11 Ala-Lys




11 Ala-Trp




11 Ala-Asp




11 Ala-D-Phe




11 Ala-Nle




11 D-Val-D-Thr




11 D-Val-Gly






11 D-Val-Ala




11 D-Val-D-Val




11 D-Val-Pro**11 D-Val-Lys****11 D-Val-Trp**


11 D-Val-Asp




11 D-Val-D-Phe




11 D-Val-Nle




11 Pro-D-Thr






11 Pro-Gly




11 Pro-Ala




11 Pro-D-Val**11 Pro-Pro****11 Pro-Lys**


11 Pro-Trp






11 Pro-Asp




11 Pro-D-Phe




11 Pro-Nle**11 Lys-D-Thr****11 Lys-Gly**


11 Lys-Ala




11 Lys-Lys




11 Lys-Trp




11 Lys-Asp




11 Lys-D-Phe




11 Lys-Nle




11 Trp-D-Thr




11 Trp-Gly




11 Trp-Ala




11 Trp-D-Val




11 Trp-Pro




11 Trp-Lys




11 Trp-Asp




11 Trp-D-Phe




11 Trp-Nle




11 Asp-D-Thr




11 Asp-Gly




11 Asp-Ala




11 Asp-D-Val




11 Asp-Pro




11 Asp-Lys




11 Asp-Asp




11 Asp-D-Phe




11 Asp-Nle




11 D-Phe-D-Thr




11 D-Phe-Gly




11 D-Phe-Ala




11 D-Phe-D-Val




11 D-Phe-Pro




11 D-Phe-Lys




11 D-Phe-Trp




11 D-Phe-Asp




11 D-Phe-D-Phe




11 D-Phe-Nle




11 Nle-D-Thr




11 Nle-Gly




11 Nle-Ala




11 Nle-D-Val




11 Nle-Pro




11 Nle-Lys




11 Nle-Trp



11 Nle-Asp



11 Nle-D-Phe



11 Nle-Nle






Figure S4. MALDI-TOF MS of Rapalogs **12** in Table 2


12 D-Thr-D-Thr




12 D-Thr-Gly




12 D-Thr-Ala







12 D-Thr-Pro




12 D-Thr-Lys




12 D-Thr-Trp




12 D-Thr-Asp




12 D-Thr-D-Phe




12 D-Thr-Nle




12 Gly-D-Thr




12 Gly-Gly




12 Gly-Ala (12b)




12 Gly-D-Val




12 Gly-Pro




12 Gly-Lys




12 Gly-Trp




12 Gly-Asp




12 Gly-D-Phe




12 Gly-Nle




12 Ala-D-Thr




12 Ala-Ala




12 Ala-D-Val




12 Ala-Pro




12 Ala-Lys




12 Ala-Trp




12 Ala-Asp




12 Ala-D-Phe






12 Ala-Nle




12 D-Val-D-Thr







12 D-Val-Pro




12 D-Val-Lys




12 D-Val-Trp




12 D-Val-Asp




12 D-Val-D-Phe




12 D-Val-Nle




12 Pro-D-Thr




12 Pro-Gly




12 Pro-Ala




12 Pro-D-Val




12 Pro-Pro




12 Pro-Lys




12 Pro-Asp




12 Pro-D-Phe




12 Pro-Nle




12 Lys-D-Thr




12 Lys-Gly




12 Lys-Ala




12 Lys-D-Val




12 Lys-Pro




12 Lys-Lys




12 Lys-Trp




12 Lys-Asp




12 Lys-D-Phe




12 Lys-Nle




12 Trp-D-Thr




12 Trp-Gly




12 Trp-Ala




12 Trp-D-Val




12 Trp-Pro




12 Trp-Lys




12 Trp-Asp




12 Trp-D-Phe




12 Trp-Nle




12 Asp-D-Thr




12 Asp-Gly




12 Asp-Ala (12a)




12 Asp-D-Val




12 Asp-Pro




12 Asp-Lys




12 Asp-Asp




12 Asp-D-Phe




12 Asp-Nle




12 D-Phe-D-Thr




12 D-Phe-Gly




12 D-Phe-Ala




12 D-Phe-D-Val




12 D-Phe-Pro




12 D-Phe-Lys




12 D-Phe-Trp




12 D-Phe-Asp




12 D-Phe-D-Phe




12 D-Phe-Nle




12 Nle-D-Thr




12 Nle-Gly




12 Nle-Ala




12 Nle-D-Val




12 Nle-Pro




12 Nle-Lys




12 Nle-Trp



12 Nle-Asp



12 Nle-D-Phe



12 Nle-Nle






Figure S5. Additional representative titration curves derived from fluorescence anisotropy (FA) competition assay of rapalogs. The percentage of FA was plotted against the rapalog concentration.


Compound 11 (D-Thr-D-Thr)




Compound 11 (D-Thr-Pro)




Compound 11 (D-Thr-Asp)




Compound 11 (D-Thr-Gly)




Compound 12 (D-Thr-Gly)



Compound 12 (D-Thr-Asp)



Compound 12 (D-Thr-Pro)



Compound 12 (D-Thr-Trp)

